Reported Late Monday, Everest Medicines And Kezar Life Sciences Received IND Approval From China's NMPA For The PALIZADE Trial In Lupus Nephritis
Portfolio Pulse from Benzinga Newsdesk
Everest Medicines and Kezar Life Sciences, Inc. (NASDAQ:KZR) received IND approval from China's NMPA for the Phase 2b PALIZADE trial of zetomipzomib in lupus nephritis patients. Everest will enroll patients in China, leveraging its exclusive rights to develop and commercialize zetomipzomib in Greater China and other regions. This marks a significant step in addressing lupus nephritis, a leading cause of kidney failure among 400,000-600,000 patients in China.
February 27, 2024 | 8:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kezar Life Sciences, Inc. (NASDAQ:KZR) received IND approval from China's NMPA for the Phase 2b PALIZADE trial of zetomipzomib in lupus nephritis, in partnership with Everest Medicines.
The IND approval from China's NMPA for the PALIZADE trial represents a significant regulatory milestone for Kezar Life Sciences, potentially opening up a large patient market in China. This approval, especially for a novel treatment like zetomipzomib, could significantly enhance Kezar's market position in autoimmune disease treatment, likely leading to positive investor sentiment and a potential short-term uptick in KZR's stock price.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90